Overview

Specifications

Reagent

in vivo-jetPEI®

Molecule delivered

DNA
siRNA
miRNA
Oligonucleotides

Applications

in vivo functional studies (overexpression, knock-down, CRISPR genome editing)
Cancer Research
Vaccination/immunization

Targeted organs

All organs

Injection routes

Various systemic and local administration routes

Number of transfections

eg. 100 µl of in vivo-jetPEI® delivery reagent is sufficient to perform 15 to 25 intravenous injections in mouse.

Storage

-20 ± 5 °C, for at least 12 months

Provided with

10% glucose solution


Summary

in vivo-jetPEI® is the most advanced in vivo transfection reagent for safe and efficient in vivo delivery of DNA, si/RNA and other oligonucleotides in animal models. With a track record of over 700 publications, in vivo-jetPEI® is the consensual in vivo transfection method for in vivo functional studies, cancer research and immunization/vaccination.

in vivo-jetPEI®, a reagent of choice for therapeutic applications

Table 1: Range of in vivo-jetPEI® quality grade reagents for each step of in vivo DNA, si/miRNA transfection. in vivo-jetPEI® is available as an R&D grade for fundamental research and proof of concept studies. For preclinical biodistribution and toxicology studies and early phase clinical studies, we supply a higher preclinical grade in vivo-jetPEI®. GMP in vivo-jetPEI® is the highest quality grade available to meet quality demands in Human clinical trials.

Ordering information

Reference NumberAmount of reagentAmount of 10% glucose solution
201-10G0.1 ml10 ml
201-50G0.5 ml2 x 10 ml

Bulk quantities and GMP grade reagent are available upon request. Please contact us.

Request a quote

Description

Polyvalent: in vivo delivery of DNA, si/sh/miRNA nucleic acid in any animal model including mice

The easiness of use and versatility of in vivo-jetPEI® allows scientists to perform gene function studies by overexpressing or downregulating a gene in any organ/tissue of interest. in vivo-jetPEI® is polyvalent: it is suitable for the delivery of nucleic acid (plasmid DNA, siRNA, shRNA, miRNA and oligonucleotides) in any animal model (mice, rat, guinea pig, dog, rabbit, monkey, etc…). Numerous Scientific publications demonstrate the successful delivery of each type of nucleic acid in different animal model.

in vivo-jetPEI® has already been used to target a wide range of organs by systemic and local injection routes. Local administration routes include subcutaneous tumor, intracerebral or intra-articular injections and topical application. The injection route largely determines the targeted organs. For example, upon intravenous injection, in vivo-jetPEI®-mediated DNA delivery leads to gene expression mainly in the lung but also in the liver, pancreas, spleen, kidney, heart, bladder and artery. Conversely, upon intraperitoneal injection, the gene of interest will be expressed in the ovary, pancreas, diaphragm, uterus and stomach (Fig. 1). To achieve organ specific gene expression, cell-specific promoters can be combined with the choice of a local injection route to restrict gene expression to an organ/tissue. Guidelines for systemic and most local injection routes are available.

Fig. 1: Organs targeted following systemic nucleic acid delivery using in vivo-jetPEI® in mice. Complexes were formed using 40 μg or 100 μg of luciferase expressing plasmid and in vivo-jetPEI® at an N/P ratio of 8, in 200 μl or 1 ml of 5% glucose and injected either through retro-orbital sinus (IV) or intraperitoneally (IP), respectively. 24 hours after injection, different organs were extracted and luciferase expression was measured or live imaging was performed using IVIS system (Perkin Elmer).

 

Easy-to-use: two-step protocol

 in vivo-jetPEI® is the reagent of choice to deliver DNA, si/sh/miRNA nucleic acid using most systemic and local injection routes. The protocol is easy to use and similar to a classical in vitro transfection: the nucleic acid and in vivo-jetPEI® reagent are mixed and directly injected into the animal model (Fig. 2).

Fig 2: in vivo-jetPEI® protocol in mice. This two-step protocol is compatible with direct injection of in vivo-jetPEI®/nucleic acid nanoparticles though any systemic or local administration routes.

Our delivery experts are available to adapt your protocol to your animal model and send you the relevant literature.

contact the Scientific Support

 

Renowned: Most advanced in vivo delivery technology for cancer research, immunization and vaccination

in vivo-jetPEI® is a powerful polymer-based reagent with unique properties. In the provided complexation solution, in vivo-jetPEI® condenses any nucleic acid into stable nanoparticles of ca. 50 nm diameter (Fig 1). These nanoparticles are sufficiently small to efficiently diffuse within tissues and enter cells by endocytosis, while protecting naked nucleic acids from degradation. At the cellular level, in vivo-jetPEI facilitates both endosomal escape using the proton sponge mechanism (Akinc et al. (2005), J Gene Med 7: 657), and crossing of the nuclear membrane (Brunner et al. (2002), Mol Ther 5: 80).

Fig. 3 in vivo-jetPEI® forms small spherical particles with plasmid DNA. in vivo-jetPEI®/DNA complexes are prepared in 5% glucose solution at N/P ratio of 10. Complexes were added on a carbon covered grid and stained with uranyl acetate. Observation was carried out under a TEM. Bar is 100 nm. Complexes produced in glucose solution are discrete spheres having a mean size of 50 +/- 30 nm (Courtesy J-S Remy, Laboratoire Chimie Génétique, CNRS UMR 7514, Illkirch, France).

Successful: Used from fundamental research to Human clinical trials

Due to its reliability, in vivo-jetPEI® has been selected as a delivery vector for several drug development programs due to its safety and delivery efficiency. There are currently several ongoing clinical trials for cancer therapies, vaccination and immunization using higher quality grade GMP in vivo-jetPEI®.

FAQ

If you have any questions regarding in vivo-jetPEI®, please visit our dedicated Frequently asked questions or contact us.

Applications

in vivo functional studies

in vivo-jetPEI® is perfectly suited to study gene function in vivo and provides the easiest method for the validation of in vitro functional studies into animals.

Read more…

Cancer Therapy

in vivo-jetPEI®-based nucleic acid delivery is now widely used for tumor growth inhibition studies. As an example, the delivery of a modified siRNA against Cyclin B1 with in vivo-jetPEI® inhibits the formation of lung metastases (Fig. 4A) and in vivo-jetPEI® mediated delivery of a modified siRNA against Survivin prevents the growth of a tumor xenograft model (Fig. 4B).

Fig. 4: Tumor growth inhibition following in vivo-jetPEI® mediated delivery of modified siRNAs. (A) Mice were injected intravenously with TSA-Luc cells forming exclusively lung metastases. 2 days after cell injection, the mice were treated intravenously with 1 mg/kg of STICKY siRNA™ against cyclin B1 (N/P=12.5). Bioluminescence imaging was performed 10 days after cell injection. Data from Bonnet et al., (2013), J Control Release 170(2) :183-90. (B) Mice bearing tumor xenografts were treated intravenously with 1 mg/kg of STICKY siRNA™ against Survivin (N/P=12.5). Tumor growth was monitored after each treatment and represented as a mean tumor volume ± SEM. Data from Kedinger et al., (2013), BMC Cancer 13:338.

Read more…

Immunization/Vaccination

Following in vivo administration of plasmid DNA formulated with in vivo-jetPEI®, the expressed protein can elicit the induction of a robust and persistent immune response, hence protecting animals from different viruses or pathogens challenge.

Read more…

 in vivo gene editing using CRISPR/Cas9 system

in vivo-jetPEI®-mediated delivery of CRISPR/Cas9 system targeting tumor suppressor genes provides a flexible and effective method to investigate somatic loss-of-function alterations and their influence on tumorigenesis.

Read more…

Citations

in vivo-jetPEI® is the leading in vivo delivery method with a proven track record of peer-reviewed scientific publications, ranging from fundamental gene function studies to cancer research and vaccination studies.  Here is a list of recent publications per application:

Cancer research

Chen, C. H., Chen, P. Y., Lin, Y. Y., Feng, L. Y., Chen, S. H., Chen, C. Y., Huang, Y. C., Huang, C. Y., Jung, S. M., Chen, L. Y., Wei, K. C. (2019). Suppression of tumor growth via IGFBP3 depletion as a potential treatment in glioma., J Neurosurg , 1-12

Choe, M. H., Yoon, Y., Kim, J., Hwang, S. G., Han, Y. H., Kim, J. S. (2018). miR-550a-3-5p acts as a tumor suppressor and reverses BRAF inhibitor resistance through the direct targeting of YAP., Cell Death Dis 9, 640

Vaccination/immunization

Lee, J., Park, E. B., Min, J., Sung, S. E., Jang, Y., Shin, J. S., Chun, D., Kim, K. H., Hwang, J., Lee, M. K., Go, Y. Y., Kwon, D., Kim, M., Kang, S. J., Choi, B. S. (2018). Systematic editing of synthetic RIG-I ligands to produce effective antiviral and anti-tumor RNA immunotherapies., Nucleic Acids Res 46, 1635-1647

O’Neil, R. T., Saha, S., Veach, R. A., Welch, R. C., Woodard, L. E., Rooney, C. M., Wilson, M. H. (2018). Transposon-modified antigen-specific T lymphocytes for sustained therapeutic protein delivery in vivo., Nat Commun 9, 1325

Cao, W., Mishina, M., Amoah, S., Mboko, W. P., Bohannon, C., McCoy, J., Mittal, S. K., Gangappa, S., Sambhara, S. (2018). Nasal delivery of H5N1 avian influenza vaccine formulated with GenJet or in vivo-jetPEI((R)) induces enhanced serological, cellular and protective immune responses., Drug Deliv 25, 773-779

Functional studies

Xiao, Y., Barbosa, C., Pei, Z., Xie, W., Strong, J. A., Zhang, J. M., Cummins, T. R. (2019). Increased resurgent sodium currents in Nav1.8 contribute to nociceptive sensory neuron hyperexcitability associated with peripheral neuropathies., J Neurosci

Fujita, K., Chen, X., Homma, H., Tagawa, K., Amano, M., Saito, A., Imoto, S., Akatsu, H., Hashizume, Y., Kaibuchi, K., Miyano, S., Okazawa, H. (2018). Targeting Tyro3 ameliorates a model of PGRN-mutant FTLD-TDP via tau-mediated synaptic pathology., Nat Commun 9, 433

Wen, Q., Wu, S., Lee, W. M., Wong, C. K. C., Lui, W. Y., Silvestrini, B., Cheng, C. Y. (2019). Myosin VIIa supports spermatid/organelle transport and cell adhesion during spermatogenesis in the rat testis., Endocrinology.

Quality

Polyplus-transfection® is ISO 9001 Quality Management System accredited since 2002; this level of certification assures global customers that the supplier has established reliable and effective processes for product development, manufacturing, sales and customer support.

Each batch of in vivo-jetPEI® reagent is tested for conformity to established Quality Controls and relevant specifications. A Certificate of Analysis is provided with each vial of reagent

Testimonials

« I finished the experiments and I think in vivo-jetPEI® works great. I am very pleased with the results. Actually some of the work we have done with in vivo-jetPEI® as well as jetSI™ 10 mM has been published in Science. […] I am also very pleased with the technical assistance. Many thanks! »
 Emine E.K., Hacettepe University, Turkey 
  
« Our project is going quite well, we are working a lot with your siRNAs delivery system, and we are obtaining superb results in vivo. »
 Mattia C., L’Aquila University, Italy 
  
« in vivo-jetPEI® is a very nice reagent to work with! »
 Marie-Line G., Lady Davis Institute, Canada 
  

Protocol

To view our protocols, please fill in the fields below and click download.

Other files

Bibliography

Order by :  
Found 418 results :
Cell Linein vitro
in vivo
Delivered MoleculeReagentResults & Citations
-in vivosiRNAin vivo-jetPEI
Acosta, C., Djouhri, L., Watkins, R., Berry, C., Bromage, K., Lawson, S. N. (2014)

J Neurosci 34, 1494-509
TREK2 expressed selectively in IB4-binding C-fiber nociceptors hyperpolarizes their membrane potentials and limits spontaneous pain
More details
-in vivosiRNAin vivo-jetPEI
Aguilera-Aguirre, L., Bacsi, A., Radak, Z., Hazra, T. K., Mitra, S., Sur, S., Brasier, A. R., Ba, X., Boldogh, I. (2014)

J Immunol 193, 4643-53
Innate inflammation induced by the 8-oxoguanine DNA glycosylase-1-KRAS-NF-kappaB pathway
More details
-in vivoDNAin vivo-jetPEI
Amit, D., Hochberg, A. (2010)

J Transl Med 8, 134
Development of targeted therapy for bladder cancer mediated by a double promoter plasmid expressing diphtheria toxin under the control of H19 and IGF2-P4 regulatory sequences
More details
-in vivoDNAin vivo-jetPEI
Amit, D., Tamir, S., Birman, T., Gofrit, O. N., Hochberg, A. (2011)

Int J Clin Exp Med 4, 91-102
Development of targeted therapy for bladder cancer mediated by a double promoter plasmid expressing diphtheria toxin under the control of IGF2-P3 and IGF2-P4 regulatory sequences
More details
-in vivoDNAin vivo-jetPEI
Angelos, P. C., Winn, S. R., Kaurin, D. S., Holland, J., Wax, M. K. (2011)

Arch Facial Plast Surg 13, 185-9
Evaluating revascularization and flap survival using vascular endothelial growth factor in an irradiated rat model
More details
-in vivoDNAin vivo-jetPEI
Ansaldi, D., Hod, E. A., Stellari, F., Kim, J. B., Lim, E., Roskey, M., Francis, K. P., Singh, R., Zhang, N. (2011)

PLoS ONE 6, e25093
Imaging pulmonary NF-kappaB activation and therapeutic effects of MLN120B and TDZD-8
More details
-in vivosiRNAin vivo-jetPEI
Arnandis, T., Ferrer-Vicens, I., Torres, L., Garcia, C., Garcia-Trevijano, E. R., Zaragoza, R., Vina, J. R. (2014)

Biochem J 459, 355-68
Differential functions of calpain 1 during epithelial cell death and adipocyte differentiation in mammary gland involution
More details
-in vivosiRNAin vivo-jetPEI
Batassa, E. M., Costanzi, M., Saraulli, D., Scardigli, R., Barbato, C., Cogoni, C., Cestari, V. (2010)

Neurosci Lett 471, 185-8
RISC activity in hippocampus is essential for contextual memory
More details
-in vivomodified siRNA, Poly (I:C)in vivo-jetPEI
Besch, R., Poeck, H., Hohenauer, T., Senft, D., Hacker, G., Berking, C., Hornung, V., Endres, S., Ruzicka, T., Rothenfusser, S., Hartmann, G. (2009)

J Clin Invest 119, 2399-411
Proapoptotic signaling induced by RIG-I and MDA-5 results in type I interferon-independent apoptosis in human melanoma cells
More details
-in vivoDNAin vivo-jetPEI
Bhang, H. E., Gabrielson, K. L., Laterra, J., Fisher, P. B., Pomper, M. G. (2011)

Nat Med 17, 123-9
Tumor-specific imaging through progression elevated gene-3 promoter-driven gene expression
More details